The 13th Annual Personalized Medicine Conference will define the landscape, outlook and next steps for personalized medicine in science, business and policy.
November 14 - 16, 2017
Joseph B. Martin Conference Center
Harvard Medical School
Speakers for the 13th Annual Personalized Medicine Conference provide head shots and biographical descriptions on a rolling basis.
Marcia A. Kean, M.B.A.
Chairman, Strategic Initiatives
Feinstein Kean Healthcare
Marcia A. Kean is Chairman, Strategic Initiatives, of Feinstein Kean Healthcare, a leading strategy and communications firm dedicated to advancing innovation in the life sciences and healthcare. For more than three decades, Marcia has consistently identified and helped drive adoption of new waves of technology that have transformative impact on healthcare. Marcia founded the first personalized medicine communications practice in the U.S., and has been active in the field for 15 years. Most recently, she co-authored with Daryl Pritchard, Ph.D., Senior Vice President, Science Policy, Personalized Medicine Coalition, a study of adoption at eight leading healthcare organizations, entitled "Emerging Models for Clinical Adoption of Personalized Medicine," published in The Journal of Precision Medicine in August 2017.
Marcia led communications for the National Cancer Institute’s first-generation data exchange and bioinformatics program for seven years. She served as co-Vice Chair of the Advisory Committee of the Institute of Medicine’s Cancer Informatics Workshop. She founded and chairs the Advisory Committee of the “Turning the Tide Against Cancer Through Sustained Medical Innovation”, a national initiative on policy co-convened by the Personalized Medicine Coalition, American Association for Cancer Research and Feinstein Kean Healthcare. She leads Feinstein Kean’s partnership in iConquerMS™, a novel patient-powered research initiative to accelerate multiple sclerosis research with an online data collection and analysis platform. Marcia holds an M.B.A. from New York University and a B.A. from the University of California at Berkeley.
Sean Khozin, M.D., M.P.H.
Associate Director (Acting)
Oncology Center of Excellence
Dr. Khozin is a thoracic oncologist, acting associate director at FDA’s Oncology Center of Excellence, and the founding director of Information Exchange and Data Transformation (INFORMED), a data science and technology incubator focused on supporting innovations that enhance FDA’s mission of promotion and protection of the public health. Drawing from the expertise of a diverse group of oncologists, data scientists, statisticians and entrepreneurs-in-residence, INFORMED is expanding organizational and technical infrastructure for big data analytics and examining modern approaches in evidence generation to support regulatory decisions. The research portfolio of INFORMED includes investigations into real world data for clinical evidence generation, biosensors and the internet of things to quantify intrinsic and extrinsic factors influencing the patient’s experience, machine learning and artificial intelligence, and blockchain to enable secure exchange of health data at scale.
Previously, Dr. Khozin was in private practice in New York City, an attending physician at St. Vincent’s Hospital in Manhattan, and an entrepreneur specializing in building health information technology systems with virtual patient management (including video, structured email, short message service and remote biometric monitoring) and point-of-care data visualization and analytics capabilities.
Eric G. Klein, Pharm.D.
Senior Director, Oncology, Global Patient Outcomes,
Real World Evidence
Eli Lilly and Company
Dr. Klein is currently Senior Director, Oncology in the Global Patient Outcomes and Real World Evidence Department at Eli Lilly and Company. In this role, Dr. Klein leads the Outcomes Research team supporting the Oncology Business Unit and is responsible for the health economic, outcomes research, and real-world evidence capabilities supporting Lilly’s early and late phase drug development efforts in oncology.
Dr. Klein has spent the last 20 years is leadership roles responsible for various aspects of the Outcomes Research and Real World Evidence organization at Lilly. Dr. Klein joined the Outcomes Research organization of Lilly USA in January of 1998 where he spent six years focused on building the organizations capabilities. In September 2004, Dr. Klein transitioned to Lilly’s Global Health Outcomes organization where over the next six years he held leadership roles associated with development across product and program phase research as well as the development of business management and operations capabilities including quality, capacity planning, capability management and development, strategic planning, and project management. In January of 2010, Dr. Klein returned to Lilly USA to assume responsibilities for strategic transformation efforts within the Outcomes Research organization and then in 2011, he took on responsibility for the Regional Outcomes Research teams globally. Dr. Klein assumed his current responsibilities in Oncology drug development in 2014.
Thomas Lynch, Jr., M.D.
Executive Vice President
Chief Scientific Officer, Research & Development
Dr. Thomas Lynch joined Bristol-Myers Squibb in March 2017 as Executive Vice President and Chief Scientific Officer of Research & Development, bringing broad leadership experience, significant experience in drug development and a deep understanding of the patient perspective as a treating oncologist. He previously served as a Director on Bristol-Myer Squibb's Board from 2013 - 2017.
Tom has more than 30 years of medical, management and leadership experience, including more than 23 years at Massachusetts General Hospital (MGH). He served as Chairman and Chief Executive Officer of Massachusetts General Physicians Organization and as a member of the MGH Board from 2015 to 2017. Before his roles as Chairman and CEO at MGH, Tom served as the Director of Yale Cancer Center and was the Richard and Jonathan Sackler Professor of Internal Medicine at the Yale School of Medicine from 2009 to 2015. He also served as the Physician in Chief of Smilow Cancer Hospital, Yale New Haven from 2009 to 2015. Prior to 2009, he served as Professor of Medicine at Harvard Medical School and Chief of Hematology/Oncology at Massachusetts General Hospital. While at MGH in 2004, Tom was part of the team credited with the significant discovery that certain genetic mutations in lung cancer patients caused therapies to work for some individuals and not for others.
Tom is a member of the American Association for Cancer Research, the American Society of Clinical Oncology, and the International Association for the Study of Lung Cancer.
Susan brings 29 years of journalistic experience to her role as Publisher for Genome magazine — the first consumer magazine exclusively devoted to personalized medicine and genomics. With over 300,000 copies distributed across the US each quarter, Genome covers the personalized medicine stories of today and the breakthroughs of tomorrow, so that patients have the information they need to get the targeted treatments they deserve.
Prior to its launch, she spent 10 years as the publisher of CURE — a magazine for cancer patients, survivors and caregivers. During her tenure at CURE, she also served as Vice President of Patient Engagement for McKesson Specialty Health. In 2016, Susan was honored by Folio as one of the “Top Women in Media” for her entrepreneurial efforts in magazine publishing and media. She has over 20 years of experience delivering first-class sales and management strategies to leading and start-up media and health care organizations, and is especially skilled at creating collaborative partnerships that result in highly respected educational offerings for patients and health care providers.
Howard McLeod, Pharm.D.
DeBartolo Family Personalized Medicine Institute
Moffitt Cancer Center
Dr. Howard McLeod is Medical Director of the DeBartolo Family Personalized Medicine Institute at the Moffitt Cancer Center. He is chair of the Department of Individualized Cancer Management and a State of Florida Endowed Chair in Cancer Research. He is also a Senior Member of the Division of Population Sciences and Professor at the University of South Florida.
Dr. McLeod is chair of the NHGRI eMERGE network external scientific panel and a recent member of the FDA committee on Clinical Pharmacology and the NIH NHGRI Advisory Council. Since 2002, Dr. McLeod has been vice chair for Pharmacogenomics for the NCI clinical trials group CALGB/ALLIANCE, overseeing the largest oncology pharmacogenomics portfolio in the world. Dr. McLeod is also a 1000 talent scholar of China and a Professor at Central South University in Changsha, China. Dr. McLeod is an active entrepreneur, serving on the Board of Directors, Scientific Advisory Board and as a domain expert consultant to publically traded and privately held companies. He has also founded both for-profit and non-profit companies in the USA and China. Howard has published more than 500 peer reviewed papers on pharmacogenomics, applied therapeutics or clinical pharmacology and continues to work to advance individualized medicine.
Lincoln Nadauld, M.D., Ph.D.
Executive Director, Precision Medicine, Precision Genomics
Dr. Lincoln Nadauld is the Executive Director of Precision Medicine and Precision Genomics at Intermountain Healthcare. His team is extending the lives and improving quality of life for late-stage cancer patients locally, nationally and internationally. Dr. Nadauld helped to develop technologies at Stanford University that identify DNA changes in cancer to predict whether or not a targeted cancer drug might be effective for a specific patient.
Originally from Utah, Dr. Nadauld attended Brigham Young University for his undergraduate degree and went on to complete medical and doctoral degrees followed by an internship and residency at the University of Utah. He completed a clinical fellowship in medical oncology and Ph.D. at Stanford University where he continues to be involved in research collaborations. He was awarded the prestigious Young Investigator Award by the American Society of Clinical Oncology and the Career Development Award of the National Cancer Institute. His research has been featured in many publications, including the Journal of Oncology Practice, a publication of the American Society of Clinical Oncologists.
Joshua Ofman, M.D., M.S.H.S.
Senior Vice President, Global Value, Access
Joshua Ofman is currently the Senior Vice President of Global Value, Access & Policy at Amgen. He received his advanced medical training in Gastroenterology from UCLA and his Health Services Research training from the RAND/UCLA/VA program. He formally was a member of the academic faculty in the Department of Medicine, UCLA School of Medicine, Cedars-Sinai Medical Center. Dr. Ofman also served as the Senior Vice President of Zynx Health Inc., a consulting company focused on evidence-based clinical information for quality improvement, and reimbursement and health economics strategy for life sciences companies.
Dr. Ofman currently represents Amgen on the Boards of Directors of California Life Sciences Association (CLSA), Biotechnology Innovation Organization (BIO), and Chairman of the Boards of Directors for the National Pharmaceutical Council for 2017 (NPC).
Global Marketing Director, Health and Life Sciences Group
Bryce Olson is the Global Marketing Director for Intel’s Health and Life Sciences group. One of the areas he focuses on is bringing technology and science together in the exciting area of genomics and precision medicine with a powerful message on how this saves lives. Genomic sequencing and precision medicine gave him a life he didn’t think he’d get to live.
Bryce is inspired by connecting the advances in life sciences into clinical settings and helping patients understand these new opportunities. He is a sought after keynote speaker both locally and nationally, and his story has been covered by both local and national media. Bryce also started FACTS (‘Fighting Advanced Cancer Through Songs’), a movement that uses the power of music to build awareness for a new way to fight cancer and bring molecular testing and precision medicine to other advanced cancer patients. In 2017, Bryce wrote and co-produced a rock-n-roll album with proceeds going towards the FACTS movement, that brought together a variety of Portland, Oregon based musicians and singers including Jenny Conlee from the Decemberists, Martha Davis from the Motels, Pete Krebs, and Michelle DeCourcy – all four of whom are also cancer survivors.
Ronald A. Paulus, M.D., M.B.A.
Ronald A. Paulus, M.D., M.B.A., is President and CEO of Mission Health, a $1.7 billion integrated health system serving all of western North Carolina – a region older, poorer, sicker and less likely to be insured than state and national averages. During his tenure, Mission Health has reduced inpatient mortality by more than half, achieved six-sigma medication safety results, improved patient experience to above the 90th percentile and became the only health system ever designated as one of the nation’s Top 15 Health Systems for four consecutive years and five of six years (Thomson Reuters in 2012, and its successor Truven Health Analytics/IBM Watson in 2013-2015 and 2017).
Before joining Mission Health, Dr. Paulus served as Executive Vice President, Clinical Operations and Chief Innovation Officer for Geisinger Health System as well as co-founder, President and later CEO of CareScience, Inc., later acquired by Premier, Inc.
Dr. Paulus has been named one of Modern Healthcare’s Top 50 Most Influential Physician Executives and Leaders several times, and was recently among the Top 15 on that list. Dr. Paulus received his M.D. degree from The School of Medicine, University of Pennsylvania, and his M.B.A., concentration in healthcare management, and B.S. in Economics from The Wharton School, University of Pennsylvania.
Steven D. Pearson, M.D., M.Sc.
Institute for Clinical and Economic Review
Steven D. Pearson is the Founder and President of the Institute for Clinical and Economic Review (ICER), an independent non-profit organization that evaluates the evidence on the value of medical tests, treatments and delivery system innovations to encourage collaborative efforts to improve patient care and control costs. Prominent among its evidence reports are ICER reviews of new drugs that include full assessments of clinical and cost-effectiveness along with suggested “value-based price benchmarks” to inform policymakers and guide price and coverage negotiation.
Dr. Pearson is a Lecturer in the Department of Population Medicine at Harvard Medical School and also serves as Visiting Scientist in the Department of Bioethics at the National Institutes of Health. He received his medical degree from UCSF and completed an internal medicine residency and research fellowship at Brigham and Women’s Hospital. From 2005 - 2006, he served during the Bush administration as Special Advisor on Technology and Coverage Policy within the Coverage and Analysis Group at the Centers for Medicare and Medicaid Services. Dr. Pearson has also been a Senior Visiting Fellow at England’s National Institute for Health and Care Excellence (NICE), a Board Director of HTAi, the international society of health technology assessment agencies, and the Vice Chair of the Medicare Evidence Development and Coverage Advisory Committee (MedCAC).
Michael Pellini, M.D., M.B.A.
Michael Pellini, M.D., joined Foundation Medicine as President and Chief Executive Officer in May 2011 and transitioned to Chairman in February 2017. As a physician with more than 20 years of operating experience with companies at the forefront of the clinical diagnostics and laboratory industries, Dr. Pellini brings a breadth of understanding in personalized medicine, with a particular interest and focus in oncology. He currently serves as a member of the Board of Directors for Tango Therapeutics, Singular Genomics, the Personalized Medicine Coalition and Mass BIO, in addition to his Board Chair position with Foundation Medicine. Dr. Pellini is a member of the President’s Leadership Council for the Sydney Kimmel Medical School at Thomas Jefferson University.
Global Head of Life Sciences
Kristin Ciriello Pothier is the Global Head of Life Sciences for the Parthenon-EY practice of Ernst & Young LLP and the creator of EY Precision Medicine™. She has more than 20 years of experience in management consulting and research in the life sciences industry. She is a noted speaker, workshop leader and writer in life sciences. She is also a clinical laboratory and life sciences innovation expert, helping develop product and service strategies worldwide for investors, corporations, and medical institutions. Her book, Personalizing Precision Medicine: A Global Voyage From Vision To Reality, was released in August of 2017. Earlier in her career, Kristin was a partner and owner of Health Advances, a healthcare consulting firm, and a research scientist at Genome Therapeutics and at Genzyme. She earned a B.A. in Biochemistry from Smith College and an M.S. in Epidemiology, Health Management, and Maternal and Child Health from the Harvard School of Public Health.
Daryl Pritchard, Ph.D.
Senior Vice President
Personalized Medicine Coalition
Daryl Pritchard, Ph.D., is the Senior Vice President of Science Policy at the Personalized Medicine Coalition (PMC), where he leads PMC’s efforts to increase awareness and understanding of personalized medicine; identify and address barriers to the adoption of personalized medicine into the health care system; and develop and promote appropriate clinical, health care infrastructure, regulatory, and payment policies.
Before coming to PMC, Dr. Pritchard served as the Director of Policy Research at the National Pharmaceutical Council (NPC). Prior to joining NPC, he served as the Director of Research Programs Advocacy and Personalized Medicine at the Biotechnology Industry Organization (BIO).
Dr. Pritchard received his Ph.D. and master’s degree in genetics from the George Washington University, and completed a post-doctoral research fellowship at the Children’s National Medical Center. He was awarded the first American Society of Human Genetics (ASHG)/National Human Genome Research Institute (NHGRI) Fellowship in Genetics and Public Policy, where he worked as a health legislative assistant in the House of Representatives.
David B. Roth, M.D., Ph.D.
Simon Flexner Professor, Chair,
Pathology and Laboratory Medicine Director
Penn Center for Precision Medicine
David B. Roth is Simon Flexner Professor Chair of Pathology and Laboratory Medicine at the Perelman School of Medicine at University of Pennsylvania, and is the Director of Penn’s Center for Precision Medicine. He joined Penn in 2011 when he became Chair of Pathology and Laboratory Medicine, before founding Penn's Center for Personalized Diagnostics in 2012.
Prior to joining University of Pennsylvania, Dr. Roth served on the faculty of Baylor College of Medicine where he was a Professor and HHMI Investigator. He also worked at NYU where he was Chair of the Department of Pathology and directed the Medical Scientist Training Program. Dr. Roth has spent more than 20 years as an NIH-funded researcher with more than 100 published papers. He is an elected member of the Association of American Physicians, past president of the American Association of University Pathologists, and is Secretary-Treasurer of the Association of Pathology Chairs. He was recently featured in Pathologist magazine’s "Top 100 Power List."
Dr. Roth obtained his M.D. and Ph.D. from Baylor College of Medicine and a Pathology residency and postdoctoral fellowship at the National Cancer Institute.
Deborah Schrag, M.D., M.P.H.
Chief, Division of Population Sciences,
Dana-Farber Cancer Institute
Deborah Schrag is the Chief of the Division of Population Sciences within the Department of Medicine at Dana-Farber Cancer Institute. She also is a Professor of Medicine at Harvard Medical School and a Senior Physician in the center for gastrointestinal oncology at the Dana-Farber, where she focuses on the care of patients with tumors of the lower gastrointestinal tract, particularly colorectal cancer.
Dr. Schrag consults for the Center for Medicare and Medicaid Services and state health departments, and has testified before congressional panels on improving care quality and efficiency. She serves as a member of the National Cancer Policy Forum and the NCI standing study section on Health Services Organization and Delivery, and is a founding member of the American Society of Clinical Oncology’s Committee on Cancer Value. She is an Associate Editor of the Journal of the American Medical Association.
Dr. Schrag earned her medical degree from Columbia University College of Physicians and Surgeons and her master’s degree in public health from the Harvard School of Public Health. She completed her residency in internal medicine at Brigham and Women’s Hospital and a fellowship in medical oncology at Dana-Farber.
Michael S. Sherman, M.D., M.B.A.
Chief Medical Officer
Senior Vice President
Harvard Pilgrim Health Care
Dr. Michael Sherman serves as Chief Medical Officer and Senior Vice President for Harvard Pilgrim Health Care. Dr. Sherman has been a leader in driving adoption of outcomes-based provider and pharmaceutical contracts, and is responsible for Harvard Pilgrim’s medical trend management, provider engagement strategy, medical informatics, wellness and health promotion initiatives, care and disease management services, pharmacy services, NCQA accreditation and quality and utilization management programs. He serves on the faculty of Harvard Medical School’s Department of Population Medicine, as chair of the board of managers of the Harvard Pilgrim Health Care Institute, on the advisory board of the Institute for Clinical and Economic Review (ICER), and on the board of directors for the Personalized Medicine Coalition. Dr. Sherman also is the current chair for AHIP’s CMO Leadership Council, comprising chief medical officers from health plans throughout the United States.
Prior to joining Harvard Pilgrim, Dr. Sherman held leadership roles at Humana, UnitedHealth Group, and Thomson Medstat (now IBM Truven). He holds a B.A. and an M.S. in biomedical anthropology from the University of Pennsylvania and received his M.D. from Yale and M.B.A. from the Harvard Business School.
Jennifer Snow, M.P.H.
Director, Health Policy
Jennifer Snow, M.P.H., is a Director of Health Policy at Xcenda and keeps clients and stakeholders informed on the latest legislative and regulatory updates and their commercial impact. Her team analyzes the health care environment and provides strategic guidance on how to best navigate challenges to coverage and access. Ms. Snow is a subject matter expert on the Affordable Care Act, quality measures, medication adherence and federal health programs, particularly the Medicare Prescription Drug Benefit (Part D). She has experience with reimbursement and policy strategy launch plans for various therapeutic areas including cardiovascular, respiratory, mental health, diabetes, oncology and rheumatoid arthritis.
Before joining Xcenda, Ms. Snow was a Director of Policy at a large pharmaceutical manufacturer. Ms. Snow also worked at the Centers for Medicare & Medicaid Services in the Office of Exchanges, where she developed and formulated policies on essential health benefits, oversight, essential community providers and basic health plans. She also has expertise in healthcare coverage and access issues from her time with Avalere as well as her experience at Stanford University as a Senior Benefits Analyst.
Ms. Snow holds an M.P.H. from the University of North Carolina-Chapel Hill and a B.S. in Russian from Georgetown University.
Meg Tirrell, M.S.J.
Meg Tirrell joined CNBC in April 2014 as a general assignment reporter focusing on biotechnology and pharmaceuticals. She appears on CNBC's Business Day programming, contributes to CNBC.com and is based at the network's global headquarters in Englewood Cliffs, N.J.
Tirrell has covered development of new drugs for Alzheimer's, cancer and rare diseases, and tracked public health emergencies from Ebola to Zika. Her work has explored why fewer drugs are developed for children, chronicled the sequencing of her own genome, and followed the manufacturing of a flu shot from egg to pharmacy. In 2014, she revealed the agonizing decision-making behind Compassionate Use of unapproved drugs, and in 2016, she reported extensively on drug pricing controversies and the impact of politics on development of new medicines.
Prior to joining CNBC, Tirrell covered the biotechnology industry for Bloomberg News, where she also contributed to Bloomberg Television and Bloomberg Businessweek. She holds a master's degree in journalism from Northwestern University and a bachelor's degree in English and music from Wellesley College.
Stephen J. Ubl
Stephen Ubl is President and CEO of Pharmaceutical Research and Manufacturers of America (PhRMA), which represents America's leading biopharmaceutical research companies. Mr. Ubl leads PhRMA's work preserving and strengthening a health care and economic environment that encourages medical innovation, new drug discovery, and access to life-saving medicines.
"If anyone can find areas of agreement with the critics, or at least work productively with them, it may be Mr. Ubl," the New York Times' Robert Pear wrote in February 2016. "He is more conversant with the intricacies of health policy, and more adept at the politics." Ubl is routinely recognized as one of Washington’s most effective advocates, and, in 2017, was named for the second year in a row to Modern Healthcare’s “100 Most Influential People in Healthcare.” In 2016, he was named a Top Lobbyist by The Hill and a top health influencer by Medical Marketing & Media and PR Week magazines.
Alexander Vadas, Ph.D.
Alexander Vadas, Ph.D., is a Managing Director in L.E.K. Consulting’s Life Sciences practice. He joined L.E.K. in 2000 and leads the diagnostics, research tools and personalized medicine practice area. Within those areas, Dr. Vadas has worked with a range of established and emerging clients in the areas of corporate strategy, product strategy and planning and transaction support.
Alex has deep experience working for clients across diagnostics and personalized medicine including IVD product companies, research tools and technology enablers, clinical laboratories, pharmaceutical companies with personalized medicine drugs, and innovative providers and health systems seeking to implement personalized medicine approaches.
Dr. Vadas received his B.S., cum Laude, and Ph.D. in chemical engineering with a bioengineering emphasis from U.C.L.A. His doctoral work focused on the discovery and applications of novel enzymes derived from organisms that thrive in extreme environments.
Marc S. Williams, M.D., F.A.A.P., F.A.C.M.G., F.A.C.M.I.
Director, Genomic Medicine Institute
Marc S. Williams is a clinical geneticist and informaticist, and is the Director of the Genomic Medicine Institute of the Geisinger Health System in Danville, Pennsylvania. He is the co-PI of the Geisinger Electronic Medical Records in Genomics (eMERGE) project and is the Medical Director of the whole genome sequencing clinical research project.
Dr. Williams has participated in the Personalized Medicine Workgroup of the Department of Health and Human Services’ American Health Information Community Task Force, chaired the CDC’s EGAPP Stakeholder’s Group and was a member of the Secretary’s Advisory Committee for Genetics, Health and Society. He is a current member of the EGAPP working group and is a past member of the ACMG Board of Directors. He previously served as Vice President for Clinical Genetics and is past chair of the ACMG Committee on the Economics of Genetic Services and founded the ACMG Quality Improvement Special Interest Group. Dr. Williams serves on the the Scientific Advisory Boards of the Clinical Pharmacogenetic Implementation Consortium (CPIC) and the NIH Undiagnosed Diseases Project. Dr. Williams was also elected a fellow of the American College of Medical Informatics in 2016.
He has authored more than 130 articles on a variety of topics including the economic evaluation and value of genetic services, implementation of genomic medicine and the use of informatics to facilitate genomic medicine.